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ABSTRACT
There is a need among patients suffering from drug-resistant epilepsy (DRE) for more efficient and
less toxic treatments. The objective of the present study was to assess the safety, feasibility, and
potential efficacy of autologous bone marrow cell transplantation in pediatric patients with DRE.
Two females and two males (11 months to 6 years) were enrolled and underwent a combined
therapy consisting of autologous bone marrow nucleated cells (BMNCs) transplantation (intrathe-
cal: 0.5 3 109; intravenous: 0.38 3 109–1.72 3 109) followed by four rounds of intrathecal bone
marrow mesenchymal stem cells (BMMSCs) transplantation (18.5 3 106–40 3 106) every 3
months. The BMMSCs used were a unique population derived from CD271-positive cells. The neu-
rological evaluation included magnetic resonance imaging, electroencephalography (EEG), and cog-
nitive development assessment. The characteristics of BMMSCs were evaluated. Four intravenous
and 20 intrathecal transplantations into the cerebrospinal fluid were performed. There were no
adverse events, and the therapy was safe and feasible over 2 years of follow-up. The therapy
resulted in neurological and cognitive improvement in all patients, including a reduction in the
number of epileptic seizures (from 10 per day to 1 per week) and an absence of status epilepticus
episodes (from 4 per week to 0 per week). The number of discharges on the EEG evaluation was
decreased, and cognitive improvement was noted with respect to reactions to light and sound,
emotions, and motor function. An analysis of the BMMSCs’ characteristics revealed the expression
of neurotrophic, proangiogenic, and tissue remodeling factors, and the immunomodulatory poten-
tial. Our results demonstrate the safety and feasibility of BMNCs and BMMSCs transplantations
and the considerable neurological and cognitive improvement in children with DRE. STEM CELLS
TRANSLATIONAL MEDICINE 2018;7:20–33
SIGNIFICANCE STATEMENT
This study, to the authors’ knowledge, for the first time demonstrates safety, feasibility, and
considerable neurological and cognitive improvement in children with drug-resistant epilepsy
after bone marrow nucleated cells and bone marrow mesenchymal stem cells transplantations.
Multiple transplantations were performed, causing no adverse events during 2 years of follow-
up. The authors observed neurological and cognitive improvement in all patients, significant
reduction in a number of epileptic seizures, and absence of status epilepticus episodes. The
therapy decreased the number of discharges in electroencephalography evaluation and caused
cognitive improvement in the sphere of reaction to light and sound, in the sphere of emotions,
and in the sphere of motor function.
INTRODUCTION
Epilepsy is a serious neurological disorder that
affects 65 million people worldwide and is charac-
terized by excessive electrical discharges in the
brain that cause progressive neural cell damage
and subsequent loss [1, 2]. Different types of epi-
lepsy are recognized. Because of etiology, it is
divided into four categories: idiopathic, sympto-
matic, provoked, and cryptogenic. We can also
divide the epilepsy because of its localization (e.g.,
temporal lobe epilepsy). Twenty to forty percent
of all epilepsy patients suffer from drug-resistant
epilepsy (DRE) [3]. DRE is defined as recurrent seiz-
ures that are refractory to regimens of two or
more antiepileptic drugs [4]. DRE is difficult to
treat, causing serious clinical burdens, including
disability, mortality, comorbidities, social stigmas,
as well as psychological and economic costs [3].
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Additionally, some patients with DRE experience status epilep-
ticus (SE), a life-threatening condition characterized by seizures
lasting 30 minutes or longer. SE requires prompt recognition and
immediate action [5, 6]; however, even with adequate treatment,
the overall mortality of SE is as high as 30%. SE survivors have seri-
ous morbidities, including developmental delays, cognitive impair-
ments, chronic epilepsy, and recurrent SE [7–10].
The established standard treatment for DRE and SE includes
corticosteroids, adrenocorticotropic hormone, immunoglobulins,
plasmapheresis, and monoclonal antibodies [11]. All of the exist-
ing alternative SE treatments, including hippocampal resection
surgery, a ketogenic diet, and use of cannabinols, are connected
with serious side effects. Causal treatments that target the
dynamic and complex process of epileptogenesis have not been
developed for SE [12].
It is well known that seizures cause neuronal death, leading to
the development of an inflammatory response and an immuno-
logical reaction. In addition, the loss of gamma-amino butyric acid
(GABA)-ergic interneurons and anticonvulsant glial-derived neuro-
trophic factor (GDNF)-expressing astrocytes results in a decreased
threshold of neuronal excitation [13, 14]. Thus, to target DRE both
in the context of SE and as an independent entity, basic pathologi-
cal and physiological processes should be addressed, including
chronic immunological reactions, inflammation, neuroprotection,
and the restoration of the proper excitation threshold. The lack of
efficient antiepileptic drug therapy and the undesirability of alter-
native methods, especially neurosurgery for intractable epilepsy,
make it necessary to develop novel therapeutic approaches.
Different types of cell therapies have been developed in recent
decades, with many therapies demonstrating clinical efficiency, for
example, in myocardial infarction, wound healing, and graft-versus-
host disease (GVHD). Indeed, some of these therapies have sparked
hope for the treatment of previously incurable diseases [15, 16].
Cell therapy was also shown to induce considerable improvement
in cases of peripheral nervous system regeneration after spinal cord
injuries [17]. Following encouraging results in the peripheral nerv-
ous system, other cell therapy approaches have been reported to
improve central nervous system (CNS) regeneration [18].
Cell therapy for the treatment of epilepsy comprises a few pri-
mary approaches. The first includes the surgical insertion of fetal
hippocampal neurons or GABA-producing interneurons. The aim of
these therapies is to increase the level of inhibitory neurotrans-
mitters and thereby raise seizure thresholds or dampen seizure
propagation; however, such approaches do not address the loss of
neurons due to inflammation [19]. The second approach includes
the viral delivery of inhibitory neurotransmitters [20] and support-
ive growth factors, including brain-derived neurotrophic factor
(BDNF), basic fibroblast growth factor (FGF-2) [21], GDNF [22], and
vascular endothelial growth factor (VEGF) [23]. Lastly, the cell
transplantation approach, which employs the intravenous, intra-
peritoneal, or intrahippocampal implantation of BMNCs and
mesenchymal stem cells (MSCs), aims to influence the microenvir-
onment of the injured region and stimulate regeneration [24–33].
Preclinical studies have demonstrated the usefulness of all cell
therapy approaches in reducing the number of seizures, with some
treatments also demonstrating cognitive benefits [28–30].
The first report of the transplantation of any cell type to treat
epilepsy appeared in 1998 and described a 40% reduction in seiz-
ures frequency in one patient after porcine GABA neuron implan-
tation [34]. The results of a clinical trial using the same porcine
GABA neurons demonstrated a moderate reduction of seizure
number in three patients [35].
Preclinical epilepsy trials have demonstrated the antiepileptic
potential of human cells [33, 36]. However, there have been no
reports describing human cell or tissue transplantation in patients
with DRE.
The implantation of BMNCs and MSCs appears to be among
the only proposed methods to truly address the root cause of the
pathology. BMNCs and MSCs are well known to secrete a number
of growth factors (e.g., VEGF, GDNF, hepatocyte growth factor
[HGF]) that promote neurogenesis [37]. In addition, the patho-
morphological analysis of animals undergoing MSCs transplanta-
tions has confirmed the anti-inflammatory effect of transplanted
cells, which is considered to be one of the mechanisms leading to
the observed clinical improvement.
Recent findings from the field of spinal cord injury suggest that
MSCs have a pleiotropic nature and may profoundly impact central
nervous system regeneration by activating neurogenesis. For
example, the positive influence of MSCs on neurite sprouting, syn-
apse integrity, angiogenesis stimulation, and immunomodulation
could lead to decreased demyelination by T cells and to microglia
polarization toward an M2-like regenerative phenotype [38].
All previous preclinical and clinical trials using MSCs use an
adherence-based cell isolation procedure, followed by the in vitro
expansion of a variable population of cells. In our cell therapy
approach, we used a unique population of MSCs, with our initial
cultures consisting of isolated CD2711 mesenchymal stem cells.
Our studies [39] and those of others [40–42] have demonstrated a
higher proliferation potential, level of produced cytokines, immu-
nosuppressive abilities, vascularization stimulation, and chondral
repair of MSCs derived from CD2711 BMNCs compared with
those isolated with adherence-based methods. This unique MSC
population has already demonstrated great clinical potential in
the treatment of spinal cord injury patient [17]. Based on preclini-
cal data and our previous experience, we performed a pilot study
to ascertain whether a cell therapy approach consisting of BMNCs
and CD2711 bone marrow mesenchymal stem cells (BMMSCs)
implantation would be safe, feasible, and therapeutically effective
in patients with DRE.
MATERIALS AND METHODS
Basic Study Information
The presented study was a prospective, longitudinal experiment
conducted from 2012 to 2014 at the University Children’s Hospital
in Cracow, Poland. The Jagiellonian University Medical College Bio-
ethical Committee (KBET/241/L/2011) approved the pilot study.
The parents of the enrolled pediatric patients provided written
informed consent according to the Helsinki Declaration. However,
the study has not been registered at NIH ClinicalTrials.gov. The
general data collected before the experimental therapy consisted
of age; sex; past medical history; the type of encephalopathy,
including its etiology, the type of epileptic seizures, and their fre-
quency; and a description of previous medical treatments using
anti-epileptic drugs.
Enrollment Criteria
Pediatric patients up to 6 years of age were included in the study.
The study included patients with neural infection-related (bacte-
rial or viral) and postnatal encephalopathy, including hypoxic
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ischemic encephalopathy confirmed by magnetic resonance imag-
ing (MRI). The diagnosis of DRE was supported by an electrophysi-
ology examination EEG and ineffective drug therapy. The latter
was defined as (a) the failure of an adequate trial of two tolerated,
appropriately chosen antiepileptic drug schedules, with medica-
tion compliance or (b) having failed at least to two antiepileptic
drugs, with at least one seizure per month for the previous inter-
val between epileptic episodes or 12 months. All of the patients
also presented with repeated episodes of SE.
Only children who had received no alternative treatments
were included in the study. Children with a minimum of 6 months
between the diagnosis and the initiation of experimental therapy
were enrolled. These patients were required to have shown no
improvement in their medical condition or a reduction in seizure
episode number after standard and obligatory therapeutic meth-
ods. Moreover, it was required that the patients did not exhibit
deterioration or significant improvement in their general neuro-
logical state within the 1-month period preceding the experimen-
tal therapy. Patients with focal CNS lesions (e.g., neoplastic
lesions, untreated vascular malformations) or chronic diseases
(e.g., systemic diseases) that would require long-term pharmaco-
therapy (corticosteroids, antibiotics, chemotherapeutics) were
excluded from the study. The same neurologist examined all of
the patients prior to the treatment.
Cells Preparation
Autologous bone marrow (BM) was harvested from the posterior
superior iliac crest under general anesthesia, through aspiration
from multiple punctures of the iliac ala. Bone marrow nucleated
cells (BMNCs) and BMMSCs isolation procedures were described
previously [17]. Briefly, an isolation of BMNCs from BM suspen-
sion was performed using 10% hydroxyethyl starch solution. Steril-
ity of the material was confirmed. BMNCs were isolated from the
BM sample by a density gradient centrifugation. CD2711 BMMSCs
population was isolated according to the manufacturer’s instruc-
tions (Stem Cells Technology, Vancouver, Canada, https://www.
stemcell.com). Cells were plated into tissue culture flasks in
Dulbecco’s-modified Eagle medium supplemented with 10% fetal
bovine serum (FBS), platelet-derived growth factor (PDGF) and
epidermal growth factor. After 7 days, medium was exchanged. At
confluence, the adherent cells were detached and re-seeded at
0.075 3 106 cells/75 cm2 flasks and incubated again until conflu-
ence. BMMSCs phenotype was analyzed with antibodies specific
for MSCs (CD73, CD90, CD105) and lymphocytes (CD3, CD45)
using FACSCalibur cytometer with Cellquest software (Becton
Dickinson, Franklin Lakes, NJ, https://www.bd.com). Cytogenetic
stability of cultured BMMSCs was confirmed via GTG banding and
array comparative genomic hybridization (aCGH) analysis. During
the neurosurgical procedure, the BMMSCs were administered
intrathecally via lumbar puncture. All patients were subsequently
transplanted with multiple rounds of cultured BMMSCs at passage
3 every 3–4 months using the same methodology.
Evaluation of the Cytogenetic Stability of Cultured
Mesenchymal Stem Cells
Cytogenetic stability of cultured BMMSCs was confirmed via GTG
banding. Metaphases were analyzed under an Olympus BX51
microscope with a camera (Olympus Corporation, Tokyo, Japan,
https://www.olympus-global.com) to document photomicro-
graphs. A Cytovision program (Leica Microsystem, Inc., Buffalo
Grove, IL, https://www.leica-microsystems.com) was used to
arrange chromosomes into a karyogram.
Molecular karyotyping was performed through aCGH with the
SurePrint G3 CGH ISCA v2 Microarray Kit 8 3 60K (Agilent Tech-
nologies, Santa Clara, CA, https://www.agilent.com) according to
the manufacturer’s protocol. DNA for aCGH analysis was isolated
from samples of cells prepared for autologous transplantations.
DNA was extracted using the machine and isolation QuickGene
DNA tissue S kit (Kurabo Industries, Osaka, Japan, http://www.kur-
abo.co.jp/). Arrays were analyzed through the Agilent scanner and
the Feature Extraction software (v8.1). Graphical overview was
obtained using the Agilent CytoGenomics software (v2.9.2.4).
Quantitative Real Time Polymerase Chain Reaction
Analysis
Total RNA was extracted using Universal RNA purification Kit
(EURx, Gdansk, Poland, https://eurx.com.pl/) according to manu-
facturer’s protocol. The reverse polymerase transcription of mRNA
was performed using Moloney Murine Leukemia Virus Reverse
Transcriptase (M-MLV RT) (Promega Corporation, Madison, WI,
https://www.promega.com) as provided by vendor.
Genes expression were determined by Real-Time quantitative
Reverse Transcription Polymerase Chain Reaction (qRT-PCR)
analysis on ABI PRISM 7300 Sequence Detection System (Applied
Biosystems, Foster City, CA, https://www.thermofisher.com/us/
en/home/brands/applied-biosystems.html) using Blank qPCR
Master Mix (EURx) and the following Taq-Man probes (Applied
Biosystems) for human genes: glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) - Hs02758991_g1, BDNF - Hs02718934_s1,
GDNF - Hs01931883_s1, ciliary neurotrophic factor (CNTF) -
Hs04194755_s1, nerve growth factor (NGF) - Hs01113193_m1,
HGF - Hs00300159_m1, PDGF-A - Hs00964426_m1, vascular endo-
thelial growth factor receptor 1 (FLT-1) - Hs01052937_m1, VEGF-A
- Hs00173626_m1-, heparin-binding growth factor 1 (FGF-1) -
Hs01092738_m1, FGF-2 (Hs00266645_m1), angiopoietin 1
(ANGPT-1) - Hs00375822_m1, metalloproteinase-2 (MMP-2) -
Hs00234422_m1, metalloproteinase-9 (MMP-9) - Hs00234579_m1,
indoleamine 2,3-dioxygenase (IDO1) - Hs00984148_m1, and tumor
necrosis factor-inducible gene 6 (TSG-6) - Hs01113602_m1. mRNA
expression levels were quantified by the 2 2DCt calculation using
housekeeping GAPDH as a control.
Western Blot Analysis
Protein was isolated with M-PER lysing buffer (Thermo Fisher Sci-
entific, Waltham, Massachusetts; https://www.thermofisher.com/
pl/en/home.html) containing protease and phosphatase inhibitors
(Sigma-Aldrich, St. Louis, MO, https://www.sigmaaldrich.com).
Western blot was performed with anti-GAPDH rabbit mAb (Cell
Signaling Technology, Danvers, MA, https://www.cellsignal.com)
and anti-VEGF rabbit pAb (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, https://www.scbt.com), as described previously [43].
Cytokines Stimulations
BMMSCs were seeded into 6-well plate. After reaching 85% of con-
fluence, standard medium was replaced by stimulation medium (2%
FBS) in the absence or presence of interleukin 1 b (Il-1b; Sigma-
Aldrich) or tumor necrosis factor a (TNF-a), interferon g (INF-g;
PeproTech Inc., Rocky Hill, NJ, https://www.peprotech.com). IDO1
induction cells were treated with 100 ng/ml INF-g for 48 hour and
for TSG-6 were treated with 50 ng/ml Il-1b or TNF-a for 72 hours.
Optimized stimulation protocols were described before [44, 45].
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Implantation Procedures and Regimen
All of the BM-derived cell implantation procedures were per-
formed when the patients were stable, without contraindications
for general anesthesia based on the opinion of internal medicine
and cardiology and without any serious infectious diseases, includ-
ing sepsis, immediately prior to the procedure. The BMNCs were
transplanted intravenously (i.v.) and intrathecally, whereas the
BMMSCs were injected only intrathecally. The intrathecal injec-
tions were performed into the cerebrospinal fluid via lumbar
puncture. For i.v. infusions, the cells were suspended in 0.9% NaCl
(B. Braun). For intrathecal infusions, the cells were suspended in a
5% glucose solution (Fresenius Kabi, Kutno, Poland, https://www.
fresenius-kabi.com).
The patients received a single BMNCs transplantation (0.5 3
109 cells intrathecally and between 0.38 3 109 and 1.72 3 109 i.v.)
followed by four intrathecal passage 3 BMMSCs transplantations
(dose range: 18.5 3 106–40 3 106) every 3 months (Table 1).
Cell Therapy Safety Evaluation Criteria
The safety criteria for the transplantation procedure included the
appearance of infection, fever, headache, pain, an increased level
of C-reactive protein (CRP), increased leukocytosis, allergic reac-
tion/shock, and peritransplantation complications (e.g., analgesia-
related complications, infections of the wound) for 7–14 days
after each procedure. The safety criteria for using BMNCs and
BMMSCs included infection, pain, cancer development, and the
deterioration of the neurological state. The patients were assessed
for these signs, symptoms, and pathologies over a 2-year follow-
up period.
Assessment of Treatment Follow-Up
The follow-up evaluation consisted of a neurological examination
that assessed changes in general neurological status, palsy or
paresis, muscle tension, coordination, ataxia, and the presence of
pathological extrapyramidal signs. The physical examination con-
sisted of MRI studies, which were performed 12 months after first
BMMSCs administration, and an EEG examination, which was
always performed 10 weeks after BMMSCs implantation using a
standard scalp EEG (Elmico Digi Truck EEG). An imaging-based
neurological assessment using a prolonged 12-hour Holter EEG
examination could not be performed.
Additionally, a neurodevelopmental evaluation was per-
formed. Advanced neurological deficits were ascertained in a neu-
ropsychological examination. The neuropsychological diagnosis
was based on behavioral and functional changes. The childhood
developmental scale (CDS), was used to assess younger children
(Patients 1, 2, and 3) but provides only a qualitative evaluation
[46]. The CDS is a well-standardized and normalized test that is
used to assess psychomotor neurodevelopment in children aged 2
months to 3 years. This scale assesses the domains of perception,
memory, spatial imagination, language processes, social develop-
ment, motor development, fine motor skills, object manipulation,
and visual movement coordination. Orientation ability was
assessed for the domain of perception, including following an
object visually, following the source of a sound, following an
object, and looking at the drawing. Nonverbal reactions were esti-
mated for the speech domain, including attempts to babble and
the imitation adult vocalizations.With respect to social behaviors,
reactions to contact with adults and several adult behaviors were
evaluated, including speaking, laughter, and disappearance. Also
considered were smiles in response to another’s smile, interest in
one’s own reflection, and looking in the same direction as an
adult. Gross motor activity was assessed by movement in the hori-
zontal position on the back and belly, attempts to turn the head,
turning from the back to a side, and attempts to sit, crawl, and
stand. With respect to object manipulation, the ability to grab
objects within the sight of child was assessed (e.g., grabbing and
manipulating with the rattle, pulling a string with an attached
ring, grabbing a block moving close to the fingers, reaching out to
the block, and grabbing a second block). The level of neurological
impairment of the children from the trial was so significant that
only the test suitable for children in their second and third months
of life could be used; even so, most of the exercises were still
impossible to perform.
RESULTS
BMMSCs Evaluation
A phenotypic evaluation of cultured, passage 3, CD2711 BMMSCs
allowed a comparison of their characteristics with those of gold
standard criteria established by the International Society for Cellu-
lar Therapy. More than 95% of the analyzed cells were positive for
MSC-specific markers (CD73, CD90, and CD105), and fewer than
2% of the cells were positive for the lymphocyte markers CD3 and
CD45 (Fig. 1A).
The genomic stability of cultured CD2711 BMMSCs was con-
firmed via GTG banding (not shown) and molecular karyotyping
(Fig. 1B). Both methods confirmed no chromosomal aberrations.
To shed light on the mechanism underlying the observed clini-
cal improvement, we tested the mRNA levels of several genes in
CD2711 BMMSCs from four patients. These analyses were per-
formed using cells in the steady state as well as after stimulation
with proinflammatory agents. These experiments revealed that
CD2711 BMMSCs from all four patients expressed several neuro-
trophic factors (BDNF, GDNF, CNTF, NGF, and HGF; Fig. 1C). The
BMMSCs were also observed to express genes encoding proangio-
genic (PDGF-A, Flt-1, VEGF-A, FGF-1, FGF-2, and ANGPT-1; Fig. 1D)
and tissue remodeling (MMP-2; Fig. 1E) proteins. Furthermore,
we detected VEGF dimers and monomers at the protein level in
patients’ CD2711 BMMSCs lysates (Fig. 1F). After stimulation with
the proinflammatory agents INF-g, TNF-a, and Il-1b, we observed
an increase in the expression of IDO1 (Fig. 1G) and TSG-6 (Fig.
1H). These genes are involved in the modulation of various immu-
nological responses. This analysis revealed certain differences in
CD2711 BMMSCs characteristics between patients, both in terms
of gene expression in the steady state conditions (i.e., HGF, PDGF-
A) and following proinflammatory stimulation. However, the
impact of this variability on the ultimate clinical outcome requires
further detailed analysis.
Patients’ Neurological State Before Treatment
Four children, two males and two females, were enrolled in the
study (Table 2). Both of the males had experienced acute hypoxia
during an inflammatory episode caused by bacterial sepsis at the
age of 7 months. The etiological factor was Streptococcus pneu-
moniae for the first male (Patient 1), and the cause was not identi-
fied for the second male (Patient 2). In both cases, the bacterial
inflammation resulted in diffuse hypoxic destruction of white and
grey matter and the nuclei basales, as revealed by MRI. Blood-
brain barrier damage resulted in irregular density of the brain
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Figure 1. Molecular and functional analysis of BMMSCs. (A): Percentages of positive cells for subsequent surface markers are given in table.
(B): Graphical overview of comparative genomic hybridization microarray results. Expression levels of mRNA for neurotrophic (C), proangio-
genic (D), and tissue remodeling (E) factors in patients’ BMMSCs. qRT-PCR analysis revealed expression of BDNF, NGF, HGF, PDGF-A, Flt-1,
VEGF-A, FGF-1, FGF-2, ANGPT-1, and MMP-2. Slight expression of GDNF, CNTF, and NGF was observed. No expression of MMP-9 was
detected. The results are mean values6 SD (from triplicates) of mRNA expression relative to expression of housekeeping gene—GAPDH. (F):
Western blot detection of VEGF in patients’ BMMSCs lysates. Both forms of VEGF were identified: dimer (42 kDa) and monomer (21 kDa).
The intermediary band is an effect of nonspecific reaction of antibody, observed also in manufacturer’s specification. Standardized protein
content in samples from different patients was confirmed by GAPDH detection. (G, H): qRT-PCR analysis of IDO1 and TSG-6 mRNA expression
levels in patients’ BMMSCs stimulated with proinflammatory cytokines. (G): Pretreatment of BMMSCs with INF-g caused manifestation of
IDO1 expression. (H): Moreover, stimulation of BMMSCs with either TNF-a or Il-1b revealed elevated expression of TSG-6. Pronounced effect
was observed for Il-1b. The results are mean values6 SD (from triplicates) of mRNA expression relative to expression of housekeeping
gene—GAPDH. As a control in experiments, BMMSCs in stimulation medium only (2% FBS) were utilized. Abbreviations: ANGPT-1, angiopoie-
tin 1; BDNF, brain-derived neurotrophic factor; BMMSC, bone marrow mesenchymal stem cell; CNTF, ciliary neurotrophic factor; FBS, fetal
bovine serum; FGF, fibroblast growth factor; Flt-1, vascular endothelial growth factor receptor 1; GAPDH, glyceraldehyde 3-phosphate dehy-
drogenase; GDNF, glial-derived neurotrophic factor; HGF, hepatocyte growth factor; IDO1, indoleamine 2,3-dioxygenase; Il-1b, interleukin 1
b; INF-g, interferon g; MMP, metalloproteinase; NGF, nerve growth factor; PDGF, platelet-derived growth factor; qRT-PCR, real-time quantita-
tive reverse transcription polymerase chain reaction; TNF-a, tumor necrosis factor a; TSG-6, tumor necrosis factor-inducible gene 6; VEGF,
vascular endothelial growth factor.
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cortex (Fig. 2A). Patient 1 developed signs of active hydrocephalus,
dilatation of lateral and third ventricles, and slightly increased
intracranial pressure, requiring the implantation of a ventriculope-
ritoneal shunt. CNS lesions resulted in mental and physical disabil-
ity in this case. Patient 2, in whom the etiological factor was not
identified, remained in a minimally conscious state.
A female child with a history of Klebsiella pneumoniae infec-
tion (Patient 3) experienced two episodes of hypoxia in her first
two days of life and developed hydrocephalus as a neurological
infection complication. MRI revealed diffuse hypoxic destruction
of the white and grey matter and nuclei basales. Following the
inflammatory episode, there were large volumes of periventricular
white matter malacia (Fig. 2A). The examination showed signs of
active hydrocephalus with widened lateral, third, and fourth ven-
tricles and increased intracranial pressure, which required a ven-
triculoperitoneal shunt implantation. The second female child
(Patient 4) experienced sepsis stemming from an Escherichia coli
urinary tract infection at the age of 2 months. The destruction of
central nervous system resulted in severe and progressive neuro-
psychological disability. The MRI examination revealed diffuse
hyperintense angiogenic and demyelinated regions in the white
matter, especially in the frontotemporal lobes; minimal focal
changes were observed in the nuclei basales (not shown).
The first three patients underwent neurosurgical treatment of
postinfectious hydrocephalus with ventriculoperitoneal shunts.
The males were enrolled in the experimental study after 6 months
of drug treatment in Patient 1 and 17 months in Patient 2, with no
observed improvement in their epileptic seizures. Both of these
male patients were treated with multiple drug therapy with high
doses of valproic acid, phenobarbital and levetiracetam. Patients 3
and 4 both were treated with multidrug therapy, with no positive
results for 7 months in Patient 3 and 5 years in Patient 4. The pri-
mary anti-epileptic drugs used in these patients were valproic
acid, levetiracetam, and lamotrigine. The older female child
(Patient 4) was additionally treated with clobazam, topiramate,
and corticosteroid therapy. All of these data are summarized in
Table 3.
Therapy Schedule
All of the children who received this treatment protocol were
administered with two types of cells: BMNCs and CD2711
BMMSCs. Each patient underwent five implantation procedures.
The first procedure was a single implantation of BMNCs adminis-
tered intrathecally (0.5 3 109 cells) and intravenously (Patient 1: 1
3 109 cells; Patient 2: 0.38 3 109 cells; Patient 3: 1.72 3 109 cells;
Patient 4: 0.4 3 109 cells). Beginning 1 month after this implanta-
tion, the patients received 4 intrathecal CD2711 BMMSCs implan-
tations (range 18.5 3 106–40 3 106 cells), which were performed
every 12 weeks. In total, the patients received 4 implantations of
BMNCs and 16 implantations of BMMSCs. All of the children
underwent intense neurorehabilitation within 4 weeks after every
procedure (Table 1).
Implantation and Therapy Safety Assessment
Early safety criteria of the transplantation procedure included
assessment for the following signs: infection, fever, pain,
Table 1. Therapy schedule and implanted cells number
Patient Number of transplantations
Number of cells administrated i.v. or via LP
BMNCs [3109]
BMMSCs in 5% Glc [3106]
LP IV LP
Patient 1 5 First 0.5 1 —
Second — — 25
Third — — 32.1
Fourth — — 32.8
Fifth — — 26
Patient 2 5 First 0.5 0.38 —
Second — — 22.8
Third — — 22
Fourth — — 32
Fifth — — 33
Patient 3 5 First 0.5 1.72 —
Second — — 36.8
Third — — 40
Fourth — — 36
Fifth — — 25
Patient 4 5 First 0.5 0.4 —
Second — — 20
Third — — 34
Fourth — — 18.5
Fifth — — 23
Abbreviations: —, no data; BMNCs, bone marrow nucleated cells; BMMSC, bone marrow mesenchymal stem cell; i.v., intravenously; LP, lumbar
puncture.
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irritation, headache, increased C-reactive protein levels,
increased leukocytosis, and allergic reaction shock. These cri-
teria were assessed 7–14 days after the procedure (supple-
mental online Table 1). The considered safety-related criteria
of the therapy included cancer development, deterioration of
the neurological state with increased epileptic episodes and
epileptiform discharges on EEG, and infections or intracere-
bral hemorrhage in the 2-year follow-up period. Our observa-
tions revealed only minor side effects, namely a slight
elevation of body temperature to 388C in all treated children a
few hours after transplantation. The treatment was generally
safe, and no serious late complications were observed (Sup-
plemental Information Table 1).
Reduction of Epileptic Seizures and SE Frequency
In Patient 1, epileptic seizures initially occurred 20–40 times
per week. The first improvement appeared after the second
round of BMMSCs transplantation, when epileptic episodes
decreased to 14 episodes per week, with an average of 2 per
day. Further improvement was reported after the third
BMMSCs implantation, when the number of noticeable
epileptic seizures dropped to only one per day. After the
fourth round of BMMSCs treatment, the seizures almost
disappeared, occurring sporadically with fever or pain
(Table 4).
In Patient 2, the initial number of seizures was 30–60 per
week. After the second round of BMMSCs implantation, the num-
ber of epileptic seizures decreased to 20 per week (estimated ini-
tially at 3–5 episodes per day). After the third and fourth rounds
of BMMSCs treatment, the seizures almost ceased, occurring once
or twice a week (Table 4).
A significant reduction in the number of epileptic seizures was
observed after the third round of BMMSCs treatment in Patients
3 and 4. In the younger female child (Patient 3), the number of
seizures episodes decreased from 21 per week to 2–3 times per
week. In the case of the older female child (Patient 4), the decline
was not as significant; after the third round of BMMSCs treat-
ment, the number of episodes decreased from 40 to 30 times per
week. Notably, a significant reduction in the duration of epileptic
seizures was observed in this patient. The greatest reduction in
seizures in both cases was seen after the fourth BMMSCs implan-
tation. In Patient 3, the seizure number was reduced to one epi-
sode per week, while there were only seven episodes per week in
Patient 4, with most episodes appearing during fever or infection.
In all cases, SE episodes were extremely rare after the treat-
ment (zero to one per week) in comparison with the beginning of
the treatment (one to four per week), especially in Patients 1, 2,
and 3. In Patient 4, SE episodes occurred once or twice a month
but were shorter in duration and not characterized by breathing
difficulty (Table 4).
Epileptic Seizure Characteristics Before and After
Treatment
Patient 1 developed epilepsy 2 months after the precipitating
infection, at the age of 9 months. The seizures had different char-
acteristics, varying from those located unilaterally to general
tonic-clonic seizures (Table 3). The seizures were polymorphic,
usually represented by partial-onset, unilateral seizures and myo-
clonic seizures with secondary generalization. After the treatment,
the characteristics of the seizures changed, becoming shorter and
usually focal. Night episodes of seizures have disappeared.
In Patient 2, epileptic episodes before treatment were poly-
morphic, partial, and non-generalized, unilateral or myoclonic,
and appearing during the night. After the second round of
BMMSCs treatment, the seizures become shorter and partial or
myoclonic, without secondary generalization. Nocturnal myoclonic
seizures completely disappeared (Table 3).
In Patient 3, the seizures developed in the second month
of life. The patient presented with partial-onset epileptic seiz-
ures, generally tonic with secondary generalization (i.e., tonic-
clonic seizures). Occasionally, isolated seizures manifested
vocally. In Patient 4, the epilepsy was polymorphic in character,
with tonic-clonic seizures and isolated tonic seizures episodes,
absence episodes with myoclonic seizures of the eyelids, as
well as atonic seizures. Some of the episodes occurred during
Table 2. Patients’ characteristics, state at admission, epilepsy characteristic and MRI results before treatment
Characteristics
BMNCs 1 BMMSCs
Patient 1 Patient 2 Patient 3 Patient 4
Sex M M F F
Time interval from the
illness to epilepsy
7 m 7 m 2 m 2 m
Cause of the illness Bacterial sepsis/hypoxia Bacterial sepsis/hypoxia Bacterial sepsis/hypoxia Bacterial sepsis
Etiological factor Streptococcus pneumoniae Unidentified Klebsiella pneumoniae Escherichia coli
Age (at the time of
beginning therapy)
15 m 24 m 11 m 6 y
Epilepsy type Drug resistant Drug resistant Drug resistant Drug resistant
State at admission Minimal conscious state Mental and physical
disability
Mental and physical disability Progressive, severe mental
and physical disability
MRI White and grey matter
impairment, nuclei
basales destruction,
hydrocephalus
White and grey matter
impairment, nuclei
basales destruction
White and grey matter
impairment, nuclei basales
destruction, periventricular
leucomalacia, white matter
malacia
Diffuse hyperintensive
angiogenic and
demyelinisation regions
in white matter in
frontotemporal lobes, focal
changes in nuclei basales
Abbreviations: BMNCs, bone marrow nucleated cells; BMMSC, bone marrow mesenchymal stem cell; F, female; M, male; m, months; MRI, magnetic
resonance imaging; y, years.
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the night as classic nocturnal seizures. In both cases, the char-
acteristics of the epileptic seizures changed after treatment,
becoming more frequently partial, myoclonic, and tonic, with
rare generalization (Table 3).
EEG Analysis Evaluation
In Patient 1 and Patient 2, an EEG performed before the treatment
revealed hypersynchronous sleep EEG activity with (a) groups and
series of slow theta waves, (b) single sharp waves and groups of
Figure 2.
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sharp waves, (c) groups of spike-and-slow-wave complexes of 1–2
seconds in duration, and (d) delta wave discharges (Table 3). In
Patient 1, most of the pathological epileptiform abnormalities
were registered on both occipital lobes and the left temporal
lobe. In Patient 2, these changes dominated on the right lobe,
without any specific focal changes. The spike-and-slow-wave com-
plexes had higher amplitudes (as high as 200 lV) with a tendency
towards generalization. In both cases, photostimulation and
hyperventilation did not affect EEG activity. EEG analysis after the
treatment showed a reduction in focal discharges of sharp waves
and spike-and-slow-wave complexes, and a decreased tendency
toward generalization (Fig. 2B; Table 3).
In Patient 3, the EEG showed a weak presentation of sleep
activity. While falling asleep and during irregular sleeping,
desynchronized bioelectric activity was registered. The background
was composed of a prevalence of high-voltage delta waves (3–4
Hz) with a maximal amplitude of 180 lV. Most of these discharges
appeared in both frontal regions, with alternating dominancy
between the left and right sides. The base bioelectrical activity
was mixed with numerous beta waves (15–16 Hz) with amplitude
90 mV. In frontotemporal regions, single and diffuse sharp waves
were registered. After treatment, the EEG showed a reduction in
polymorphic, high-voltage delta waves and focal discharges of
sharp waves in frontotemporal regions (Table 3).
In Patient 4, the first EEG performed before treatment
revealed weak differentiation of base activity. The dominating
activity was unclear and could not be distinguished from the
background. The bioelectrical sleep pattern was only weakly visi-
ble, with weak and sporadic sleep spindles. Over this background,
long epileptic focal series of mid- and high-voltage slow waves
mixed with sharp waves, spike waves, polyspike activity com-
plexes, or slow wave complexes were observed. The epileptiform
abnormalities were registered primarily on both frontotemporal
lobes, with dominance on the right side. The experimental treat-
ment significantly altered these EEG results, with subsequent
analysis showing decreased epileptic discharges, particularly a
reduction in continuous mid- and high-voltage delta waves, a
small percentage of typical and atypical sharp waves, and an
absence of the spike-waves and polyspike waves seen before the
treatment. The focal changes were still located primarily on the
right frontotemporal lobe (Table 3).
Neuropsychological and Cognitive Improvement
Patient 1 and Patient 3 showed severe impairment in every
domain of the CDS. In the perception domain, they initially did not
react to light, did not track objects or attendants, and did not turn
towards sound. In addition, these patients did not show any verbal
activity and could not project any sounds. With respect to motor
activity, their hands stayed clenched at all times, they did not reach
for objects, and they did not make voluntary movements. These
children presented severe social development impairment as well,
not reacting to others’ voices. Moreover, there was no emotional
connection between the patient and others, no interest in rela-
tives’ faces, and no laughter in response to another’s behavior.
In Patient 1, inflammation caused severe CNS destruction,
resulting in the necessity of oxygen supplementation with a tra-
cheotomy tube. Regarding feeding, a loss of the swallowing reflex
required an enteral nutrition tube. After the first BMMSCs implan-
tation, the child required only partial oxygen supplementation,
and after the second round of implantation, the patient’s swallow-
ing reflex was partially restored. It then became possible to feed
him orally with semi-liquid meals. In Patient 3, damage of central
nervous system integrity resulted in severe mental and physical
disability, with prevalent pyramidal symptoms and limited destruc-
tion of the optic nerve and auditory tract.
In both cases, the patients’ eyes reacted to light after the first
round of BMMSCs implantation. Moreover, the children sporadi-
cally attempted to track objects or relatives, and a single reaction
to sound manifested as turning the head toward the sound source
or freezing. Further improvement occurred after the second and
third BMMSCs implantations. Patient 1 used the enteral nutrition
tube only sporadically, and the tracheotomy tube remained open
most of the time. Both children attempted to cry due to their
emotional state. With respect to motor development, the hands
stayed more relaxed. After the fourth BMMSCs implantation,
Patient 1 began reaching for objects but without further manipu-
lation of the objects. Patient 3 began to reach for objects earlier,
after the third round of BMMSCs implantation. Emotional reac-
tions (primarily cries), more dramatic facial expressions, and sim-
ple vocalizations appeared in both patients after the first
BMMSCs implantation.
The two other children, Patients 2 and 4, initially reacted to
light but did not track objects or attendants. Moreover, they could
not concentrate their sight on objects; they did not turn towards
sounds, but they could express emotions sporadically as a
response to a strong impulse and could vocalize simple syllables.
In Patient 2, the hands stayed clenched at all times. Both of the
children could project simple sounds, such as cooing and gurgling.
The primary neurological symptoms in these cases were full-
blown pyramidal and extrapyramidal symptoms, with very intense
spasticity, especially in the lower limbs. Additionally, Patient 4
exhibited heavy ataxia of the limbs and trunk; she also expressed
her emotions more easily than the other children in the group.
Figure 2. Magnetic resonance imaging (MRI) analysis and electroencephalography (EEG) evaluation. (A): MRI analysis. Part 1A: Patient 1
MRI. T1W turbo inversion recovery magnitude (TIRM) signs of active hydrocephalus; dilatation of lateral ventricles appeared with slightly
increased intracranial pressure. Part 1B: Signs of blood-brain barrier damage resulted in irregular density of the brain cortex, slightly increased
intracranial pressure. Part 2A: Patient 2 MRI. T1W, hydrocephalus—winded lateral ventricles and third ventricle, without signs of increased
intracranial pressure; blood-brain barrier damage resulted in irregular density of the brain cortex. Part 2B: T2W, hydrocephalus without signs
of activity, without increased intracranial pressure; signs of the destruction of the nuclei basales. Part 3A: T1W diffuse hypoxic destruction of
white and grey matter and nuclei basales—post inflammatory vast areas of periventricular white matter malacia; vast areas of white matter
and cortex atrophy. Part 3B: T1W—signs of active hydrocephalus with wide lateral, third, and fourth ventricles and increased intracranial pres-
sure after implantation of ventriculoperoneal shunt; vast areas of white matter and cortex atrophy. Part 4A: T2 trim dark fluid-destruction of
nuclei basales; no signs of increased intracranial pressure. Part 4B: T2 TSE—diffuse hyperintensive angiogenic and demyelination regions in
white matter, especially in frontotemporal lobes, and minimal focal changes in nuclei basales; no signs of increased intracranial pressure. (B):
EEG evaluation. Part 1: Patient 2 EEG taken before treatment—hypersynchronous sleep EEG activity with groups and series of slow theta
waves, single and groups of sharp waves, groups of spike-and-slow-wave complexes (1–2 seconds duration), delta waves discharge located on
right sight; the spike-and-slow-wave complexes had higher amplitude, even 200 mV, with tendency to generalization; photostimulation and
hyperventilation did not affect EEG activity. Part 2: Patient 2 EEG taken after last round of bone marrow mesenchymal stem cells showed
reduction focal discharges—sharp waves of spike-and-slow-wave complexes percentage reduction with curtailment of tendency to generaliza-
tion, smaller percentage of delta waves discharge located on right sight; photostimulation and hyperventilation did not affect EEG activity.
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Slight neurological improvement was reported after the first
BMMSCs implantation. All of the patients began to concentrate
their sight longer on relatives and objects, reacted more to sound
signals, began to vocalize more syllables, and exhibited higher lev-
els of activity. Further improvement in all patients appeared after
the second, third, and fourth rounds of BMMSCs; the children
began reaching for objects, controlling their trunk and head, and
assuming a crawling position. In addition, spasticity was signifi-
cantly reduced, and a reduction in ataxia was noted in Patient 4.
Data from the neuropsychological and functional evaluations are
summarized in Table 5.
Clinical Results Summary
Collectively, 4 intravenous and intrathecal BMNC implantations
and 16 intrathecal BMMSC implantations were performed with-
out complications. No signs of infection, fever, pain, headache,
increased CRP levels, increased leukocytosis, allergic reactions, or
other post-transplantation reactions were observed during the 2-
year follow-up period.
All of the children demonstrated neurological improvement,
with significant reductions in the number of both epileptic seiz-
ures and SE episodes. The characteristics of the seizures also
changed following treatment. Improvements were also noted in
various clinical observations and confirmed via EEG examinations.
These analyses revealed decreased epileptiform discharges and
significant reductions in sharp waves and epileptic complexes. The
observed neurological and neuropsychological symptoms amelio-
ration led to improvements in the patients’ and families’ quality of
life. Meaningful improvement in clinical and quality of life
domains appeared after the third round of implantations.
DISCUSSION
Different cell therapy approaches to treat epilepsy have been pro-
posed and tested on animal models, including surgical insertion of
fetal hippocampal neurons or GABA-producing interneurons [19],
viral delivery of inhibitory neurotransmitters [20], and supportive
growth factors [21, 22], as well as intravenous, intraperitoneal, or
intrahippocampal transplantation of BMNCs and MSCs [24–32].
Bone marrow collection is a standard procedure performed
prior to autologous or allogenic BM cell transplantation [47, 48].
The safety of intravenous delivery of BMNCs and MSCs was previ-
ously demonstrated in clinical trials for many conditions, such as
GVHD [49], multiple sclerosis [50], amyotrophic lateral sclerosis
[51], and systemic lupus erythematosus [48], as well as cardiovas-
cular [52] and liver [53] diseases. The safety and feasibility of intra-
thecal BMNCs and MSCs transplantation was also demonstrated
for different adult and pediatric patients [17, 51, 54–56].
In our study, we evaluated the safety, feasibility, and potential
efficacy of a cell therapy approach with single BMNCs and multi-
ple BMMSCs transplantations as a treatment for pediatric DRE.
Here, we demonstrate that BM collection and the subsequent
intrathecal BMNCs and BMMSCs transplantations were safe and
feasible for pediatric patients with DRE, with only transient fever
being observed after implantation. Furthermore, we report that
the applied therapy itself is safe, showing no negative effects and
resulting in no deterioration of patient clinical status in a 2-year
follow-up period. Moreover, the experimental cell therapy was
performed in combination with pharmacological therapy, which
was also determined to be safe.Ta
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The cell therapy approach appeared to result in significant clini-
cal improvement, manifesting as a marked reduction in seizure num-
ber in all of the patients (from 14–60 to 1–7 per week). The first
reduction appeared after the second BMMSCs transplantation, fol-
lowed by a gradual decrease in frequency after this point.The reduc-
tion of seizure number as a result of cell or gene therapy has been
demonstrated in animal models of chronic temporal lobe epilepsy
[13, 27–30, 36, 57] as well as CA3-selective epileptogenesis [33].
Such improvements in seizure number have also been reported fol-
lowing the viral delivery of FGF-2 and BDNF [21] or GDNF [22]. Our
observations demonstrate that an autologous cell transplantation
strategy can be effective in treating epilepsy in human patients.
The range of the seizure number reduction observed in our
patients was as high as those reported in animal trials [13, 21, 22,
27–30, 33, 57]. Moreover, the observed benefit in this outcome
was much better than the only previously published attempt of
intracerebral transplantation of porcine fetal GABAergic cells to
treat an epileptic patient with intractable partial-onset seizures [34]
or patients with focal epilepsy [35]. Notably, the improvement
began gradually and persisted over consecutive transplantations,
demonstrating the need for multiple injections to achieve the
observed range of improvement. In fact, this observation confirms
our and others’ earlier reports showing the importance of a multi-
ple implantation strategy in obtaining considerable improvement in
spinal cord regeneration [17]. Importantly, a decrease in the num-
ber of seizures was not the only beneficial result of our therapy
strategy. The occurrence of SE episodes, which are life-threatening,
ceased completely in three patients and considerably decreased in
the fourth.
Interestingly, not only the number but also the types of seiz-
ures changed with treatment. At the beginning of the treatment,
the seizures were polymorphic, often tonic-clonic, and with sec-
ondary generalization. After the treatment, the seizures became
less polymorphic and more tonic, and secondary generalization
was almost never observed. This observation indicates that bio-
electric activity of the brain underwent partial normalization. This
result was in accordance with preclinical studies and reports show-
ing that MSCs can change the convulsive threshold, as demon-
strated by shortening of the tonic seizure duration [32], a decrease
in the frequency and amplitude of sharp waves in the kindling
model of epilepsy [31], and a reduction in epileptiform waves [58].
All our patients were alive at the end of the study, and we
were not able to perform any histological evaluation to ascertain
the mechanism of action. However, the mechanism of improve-
ment after human BMNCs or BMMSCs transplantations was
already elucidated using an animal epilepsy model. Chronic
inflammation is believed to be responsible for a vicious circle,
resulting in the further death of neurons and continued neurode-
generation [59]. MSCs are known for their immunomodulatory
actions [15] and have been previously reported to reduce inflam-
mation in rat hippocampal epilepsy [26, 29, 30].
BMMSCs have been demonstrated to secrete various neuro-
trophic factors, such as BDNF and GDNF, which promote neurite
outgrowth and survival [60, 61], as well as HGF, which has been
shown to stimulate myelination [62]. BMMSCs are also capable of
suppressing T-cell proliferation [63]. All of these factors would
have an impact on neurons, stimulating their proliferation, differ-
entiation, and, subsequently, the regeneration of injured brain
regions. In fact, the neuroprotective properties of MSCs against
excitotoxic cell death were already demonstrated in an in vitro
and in vivo preclinical model [24].
Although we were not able to perform any histology studies,
we confirmed the transcript expression of the growth factors
BDNF, NGF, CNTF, HGF, VEGF-A, FGF-2, as well as that of MMP-2,
in the transplanted BMMSCs in all of our patients. VEGF-A expres-
sion was also detected at the protein level in both monomer and
dimer forms. Moreover, we demonstrated the immunomodula-
tory potential of patients’ BMMSCs following in vitro treatment
with proinflammatory cytokines. Based on preclinical data and the
characteristic of the transplanted cells, we believe that the
reduced numbers of seizures and SE episodes indicate an elimina-
tion or reduction of inflammation in the affected area as well as
the neuroprotective action of the transplanted cells on neighbor-
ing neurons. In this way, the vicious circle that was responsible for
further neuronal death and continued neurodegeneration was
broken. Additionally, the partial normalization of bioelectrical
activity suggests that the transplanted cells stimulated regenera-
tion of the injured region or altered the excitation threshold of
the injured neurons.
The range of the improvement we observed for patients with
DRE shows the strong potential of our therapeutic strategy. Inter-
estingly, the degree of improvement increased over sequential
transplantations even after the cessation of the multi-therapy reg-
imen. We believe that one of the reasons for the success of cell
therapy may be the unique populations of MSCs we used for the
implantations. Previous animal epilepsy trials and clinical trials
using MSCs collected the MSCs using an adherence-based isola-
tion procedure. However, our group cultures a pure CD2711 mes-
enchymal stem cell population. Our studies [39] and those of
others [40–42] have demonstrated that CD2711 BMMSCs have a
higher proliferation potential, produce more cytokines, exhibit
stronger immunosuppressive abilities, and promote more vascula-
rization and chondral repair than MSCs isolated with adherence-
Table 4. Reduction of epileptic seizures and SE frequency
Treatment stage
Epileptic seizure frequency (number per week)
Patient 1 SE Patient 2 SE Patient 3 SE Patient 4 SE
Before
treatment
20–40 2 30–60 1 14–21 2 10–40 4
BMNCs 20–40 2 30–60 1 14–21 2 10–40 4
BMMSCs I 20–40 2 30–40 1 14–21 2 10–40 3
BMMSCs II 14 1 20 0 14–21 1 10–30 3
BMMSCs III 7 1 2 0 2–3 0 10–14 2
BMMSCs IV 1/0 0 1 0 1 0 7 2
Abbreviations: BMNCs, bone marrow nucleated cells; BMMSC, bone marrow mesenchymal stem cell; SE, status epilepticus.
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based methods. However, a direct comparison would need to be
performed to confirm our hypothesis.
We are aware that the results of this pilot study should be con-
firmed using a larger group of patients. Those studies should
include clearly defined endpoints: for example, efficacy, safety
measurements, or feasibility. As different numbers of patients will
be necessary for feasibility, treatment tolerability, and efficacy stud-
ies, these trials should also include proper power calculations for
sample size justification. Appropriate statistical methods should be
planned ahead to prove clinical and statistical goals. For example, if
efficacy will be defined as a percentage of reduction, statistical
analysis will use methods for continuous dependent variable. It
seems appropriate to also apply multivariate regression models.
Additionally, the cell dose and the frequency of transplantation
should be optimized for the best clinical effect. The possibility can-
not be excluded that engineering the cells to express even higher
levels of neuroprotective cytokines would increase their clinical
efficiency.Whether it will be possible to obtain total seizure and SE
withdrawal as well as improved bioelectrical activity normalization
remains an open question. Similarly, longer follow-up periods are
needed to determine whether patients require repeat transplanta-
tions to maintain the improvement or if the benefits will persist
even after stopping the transplantation procedure.
CONCLUSION
We report here, for the first time to our knowledge, the safety
and feasibility of using a single BMNCs and multiple BMMSCs
implantations as a cell therapy treatment for a small group of DRE
pediatric patients. Our results demonstrate that there are no early
or late adverse events associated with the transplantation proce-
dure or the therapy itself. Additionally, the treatment resulted in
substantial neurological improvement, which manifested as a
reduced number of seizures and SE episodes as well as partially
normalized bioelectrical activity in the brain. Thus, we demon-
strated the strong potential of our therapeutic approach to treat
epilepsy patients. However, because of the low number of
patients in the current study, further studies are necessary to
move this experimental treatment into standard clinical use.
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